Aditya Medi Pharma Profile
Key Indicators
- Authorised Capital ₹ 4.50 M
as on 05-07-2024
- Paid Up Capital ₹ 45.00 K
as on 05-07-2024
- Company Age 10 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.23 Cr
as on 05-07-2024
- Satisfied Charges ₹ 3.83 Cr
as on 05-07-2024
- Revenue -40.30%
(FY 2022)
- Profit -52.71%
(FY 2022)
- Ebitda -6.50%
(FY 2022)
- Net Worth 11.24%
(FY 2022)
- Total Assets -24.77%
(FY 2022)
About Aditya Medi Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.50 M and a paid-up capital of Rs 45.00 K .
The company currently has active open charges totaling ₹2.23 Cr. The company has closed loans amounting to ₹3.83 Cr, as per Ministry of Corporate Affairs (MCA) records.
Pavan Mikkilineni, Rama Mikkilineni, and Sri Mikkilineni serve as directors at the Company.
- CIN/LLPIN
U24240TG2014PTC093149
- Company No.
093149
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Feb 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Aditya Medi Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sri Mikkilineni  | Managing Director | 25-Feb-2014 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Pavan Mikkilineni | Director | 16-Nov-2022 | Current |
| Rama Mikkilineni | Director | 05-Nov-2018 | Current |
Financial Performance of Aditya Medi Pharma.
Aditya Medi Pharma Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 40.3% decrease. The company also saw a substantial fall in profitability, with a 52.71% decrease in profit. The company's net worth Soared by an impressive increase of 11.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aditya Medi Pharma?
In 2022, Aditya Medi Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 31 Mar 2023 | ₹2.42 M | Open |
Others Creation Date: 27 Feb 2021 | ₹1.99 Cr | Open |
Lakshmi Vilas Bank Limited Creation Date: 04 Sep 2020 | ₹2.34 M | Satisfied |
How Many Employees Work at Aditya Medi Pharma?
Unlock and access historical data on people associated with Aditya Medi Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aditya Medi Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aditya Medi Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
